$81.370
-1.570 (-1.93%)At close
GMED News
GMED Events
Higgs Boson Health Acquired by Globus Medical
Higgs Boson Health announced it has been acquired by Globus Medical. The Higgs Boson Health team joins Globus Medical to extend surgical intelligence beyond the operating room and across the full care pathway. "We built Higgs Boson Health on the belief that what happens before and after surgery matters as much as what happens in the operating room," said Rajeev Dharmapurikar, CEO and Co-Founder of Higgs Boson Health. "Joining Globus Medical lets us close that loop at a scale we could not reach alone, turning every recovery into insight that makes the next surgery better."
Globus Medical Acquires Higgs Boson Health
Globus Medical acquired Higgs Boson Health, a digital healthcare experience company based in Durham, NC and incubated out of Duke University.
Company Reports Q1 Revenue of $759.85M, Beating Expectations
Reports Q1 revenue $759.85M, consensus $740.83M. "We're off to a strong start in 2026 with 27% overall revenue growth and record first quarter earnings. Organic revenue grew over 13%, driven by share gains and procedural volume strength in core spine, while Enabling Technologies delivered against its pipeline and continued to expand its customer base," commented Keith Pfeil, President and Chief Executive Officer. "Disciplined execution on manufacturing and supply chain initiatives, as well as structural cost actions, coupled with operating leverage on higher volumes, drove margin expansion in excess of sales growth, which we expect to favorably impact full-year results. Our strategic priority remains centered on achieving improved surgical outcomes through the Globus ecosystem, bringing together patient selection, surgical techniques with complementary implants and technology to drive the surgical procedure, through a closed-loop surgical intelligence system."
Company Reaffirms FY26 Revenue Guidance of $3.18B to $3.22B
Consensus $4.47. Backs FY26 revenue view $3.18B-$3.22B, consensus $3.2B. The company said, "The Company reaffirms its guidance for full-year 2026 revenue to be in the range of $3.18 billion to $3.22 billion and updates its guidance for non-GAAP fully diluted EPS to be in the range of $4.70 to $4.80 from the previous range of $4.40 to $4.50."
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.








